Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2

Author:

Wagoner Jessica1,Herring Shawn1,Hsiang Tien-Ying2,Ianevski Aleksandr3,Biering Scott B.4,Xu Shuang5,Hoffmann Markus67,Pöhlmann Stefan67ORCID,Gale Michael2,Aittokallio Tero38ORCID,Schiffer Joshua T.5910,White Judith M.1112ORCID,Polyak Stephen J.11314ORCID

Affiliation:

1. Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA

2. Department of Immunology, University of Washington, Seattle, Washington, USA

3. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

4. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California—Berkeley, Berkeley, California, USA

5. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

6. Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany

7. Faculty of Biology and Psychology, University of Göttingen, Göttingen, Germany

8. Oslo Centre for Biostatistics and Epidemiology, University of Oslo and Oslo University Hospital, Oslo, Norway

9. Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA

10. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

11. Department of Cell Biology, University of Virginia, Charlottesville, Virginia, USA

12. Department of Microbiology, University of Virginia, Charlottesville, Virginia, USA

13. Department of Global Health, University of Washington, Seattle, Washington, USA

14. Department of Microbiology, University of Washington, Seattle, Washington, USA

Abstract

Imagine a future viral pandemic where if you test positive for the new virus, you can quickly take some medicines at home for a few days so that you do not get too sick. To date, only single drugs have been approved for outpatient use against SARS-CoV-2, and we are learning that these have some limitations and may succumb to drug resistance.

Funder

Ministry for Science and Culture of Lower Saxony

Academy of Finland

Bundesministerium für Bildung und Forschung

Deutsche Forschungsgemeinschaft

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Life Sciences Research Foundation

Washington Research Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3